Health Canada and the Medical Devices Bureau as Canada’s Regulatory Authority

1. Key takeaways

The regulatory authority for medical devices in Canada is Health Canada. Within Health Canada, the Medical Devices Bureau (MDB) is responsible for issuing and managing both the Medical Device Licence (MDL) and the Medical Device Establishment Licence (MDEL), while the Therapeutic Products Directorate (TPD) and the Health Products and Food Branch (HPFB) respectively carry the product review function and the compliance and enforcement function. Companies that export devices to Canada from outside the country do not benefit from any reduction in obligations on account of where the products are made: the duties that apply to a Canadian establishment apply equally to a foreign one.

• Health Canada is the single regulator for medical devices, and the Medical Devices Bureau administers the two licence types: the MDL and the MDEL.
• Obligations in Canada are deliberately split into two tracks, one aimed at the establishment and one aimed at the product, and each track has its own licence.
• Canada classifies devices into four risk classes, Class I through Class IV, and that number is the foundation of the whole classification system.
• Foreign manufacturers face the same obligations as Canadian companies, and Health Canada also conducts on-site inspections outside Canada.

2. Legal basis

The table below sets out the legal instruments and official documents on which this article relies, together with the relevant provisions, the dates, and the official sources where each item can be verified.

3. Expert insights

Insight one: the regulatory system addresses the enterprise and the product on two parallel tracks, and each track has its own licence.

Canada divides its regulatory obligations into two distinct layers. The Medical Device Establishment Licence (MDEL) targets the premises and companies that carry out importing, distributing, or the manufacturing of Class I devices. The Medical Device Licence (MDL) targets the product itself. The product-level licence is the third layer of the system: a Class II, Class III, or Class IV device must first obtain an MDL before it may be imported into Canada or sold there. In practical terms this means that a company may hold one licence, both licences, or neither, depending on which roles it performs in the supply chain, and the two licences are assessed and maintained separately.

Insight two: the four risk classes are the base number of the Canadian classification system.

The official position of Health Canada is that medical devices are divided by use-related risk into 4 classes (I, II, III, and IV). Class I carries the lowest risk, with examples such as manual wheelchairs and thermometers, while Class IV carries the highest risk, with the cardiac pacemaker given as an example. This four-class structure is not interchangeable with the systems used elsewhere: the United States uses a three-class system, and most markets in Southeast Asia use an A/B/C/D scheme. A company entering Canada cannot simply carry over a class determination made in another jurisdiction, and the class must be determined against the Canadian rules on their own terms.

Insight three: foreign companies are subject to the same obligations as Canadian companies, and the inspections also take place abroad.

The official Health Canada pages state clearly that on-site inspections are conducted both inside and outside Canada in order to confirm that companies comply with the Food and Drugs Act and the Medical Devices Regulations. The practical consequence for a foreign manufacturer is that its production site must maintain its quality system documentation and its records in an inspection-ready state at all times, because an inspection can be announced for the overseas facility just as it can for a Canadian one. Location is therefore not a factor that lowers the compliance bar in any way.

Insight four: for combination products, the classification outcome decides which licence framework applies.

Under GUI-0016, a combination product that is classified as a drug falls under the drug establishment licence (DEL) requirements, while a combination product that is classified as a medical device falls under the MDEL requirements of section 44 and the other relevant provisions of the Medical Devices Regulations. The classification conclusion therefore determines which framework applies, and a company cannot treat the same product under the device framework on one occasion and expect favourable treatment in both directions. Getting the classification right at the outset is what keeps the dossier on the correct regulatory path.

4. Practical recommendations

• At the project initiation stage, carry out a product attribute determination first, deciding whether the item is a drug, a device, or a combination product, so that the dossier is not submitted into the wrong framework.
• Build a ledger covering the two licences: record the MDL numbers and the MDEL numbers, and document the correspondence between each product and each responsible entity, entry by entry.
• Prepare foreign production sites as if an inspection could arrive at any time, keeping distribution records, complaint handling files, incident reporting procedures, and recall procedure documents available for review at short notice.
• Verify the licence status of every business partner through MDALL and through the MDEL list, and rely on no information source other than these official listings, rather than screenshots or third-party summaries.

5. Verification checklist

• □ The product has been determined to be a device, a drug, or a combination product, with the basis recorded in writing
• □ It has been confirmed whether the manufacturing site is subject to an on-site inspection by Health Canada
• □ A ledger linking MDL numbers and MDEL numbers has been established
• □ The current licence status of the target device has been verified through MDALL
• □ The partner establishment licence has been checked against the MDEL list and confirmed to be valid
• □ A Canadian contact channel able to receive notices from Health Canada has been designated

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Canadian market. Our team manages Health Canada Medical Device Licence and MDEL applications, prepares risk-classified dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com